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ABSTRACT 
 
Aim: The complications associated with diabetes and the new trend of using combination therapy 
in the management of the disease gave birth to this work, aimed at assessing the hepatotoxic and 
nephrotoxic effects of selected popularly used antidiabetic medications in type 2 diabetic patients 
within Ota, Ogun State, Nigeria.  
Study Design: The participants, diabetic (n=195) and non-diabetic (n=30) were divided into the 
following groups based on their medications: 1 (Non Diabetic control), 2 (Metformin), 3 
(Glimepiride), 4 (Glibenclamide), 5 (Metformin and Glimepiride), 6 (Meformin and Glibenclamide), 7 
(Metformin, Glimepiride and Glibenclamide) and 8 (Diabetic Dietary control).  
Methodology: Serum protein expression profiling, liver and kidney function parameters were 
assessed in participant’s blood using Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and standard laboratory methods respectively. 
Results: Glyceamic control within the diabetic groups was 29.23%. Urea concentration was 
significantly increased (p < 0.05) in groups 5 and 7 compared with groups 1 and 8 while the serum 
creatinine levels in the different groups showed no significant difference. Activities of alkaline 
phosphatase and aspartate aminotransferase increased significantly (p < 0.05) in group 5 
compared with groups 1 and 8. A low molecular weight protein likely to be Leptin (molecular weight 
18 kDa) was over-expressed in all the diabetic groups.  
Conclusion: This study shows that use of multiple rather than single drugs caused significant 
functional changes in the liver and kidney. The control of diabetes may best be carried out with 
dietary control and lifestyle modification as well as good therapeutic drug monitoring for safe 
assessment of baseline organ function. 
 
 
Keywords: Diabetes; liver function markers; kidney function markers; protein profile. 
 
1. INTRODUCTION 
 
Diabetes mellitus is an endemic metabolic 
disease characterised with hyperglycemia; which 
can be due to either the inability of the pancreas 
to produce enough insulin, or inability of cells to 
respond to the insulin produced. It is a complex, 
chronic illness requiring continuous medical care 
with multifactorial risk-reduction strategies 
beyond glycemic control [1]. A chronic hyper-
glycemic condition in diabetes is associated with 
long term damage, dysfunction, and failure of 
various organs, such as eyes, kidneys, nerves, 
heart, and blood vessels [2]. Diabetes can be 
classified into Type I, Type II, and Gestational 
diabetes. Type II diabetes has been reported as 
the more prevalent form and has its underlying 
metabolic causes with combined effects of 
impairment in the insulin mediated glucose 
disposal and defective secretion of insulin by the 
β-cells of the pancreas [2]. Various genetic and 
environmental factors can result in the 
progressive loss of β-cell mass and/or function 
that manifests clinically as hyperglycemia in both 
type I and type II diabetes [3]. The leading cause 
of this metabolic disorder in Africa today include: 
aging population, increased urbanization; which 
can be due to changes in life style, dietary intake, 
lack of physical exercise, physiological stress, 
which is associated with obesity, a great risk 
factor of diabetes [4]. 
 
Amongst the African Countries, Nigeria has the 
highest number of people living with diabetes 
(about 3 million people) [5]. This growth in 
diabetes prevalence, driven principally by 
increasing prevalence of type II diabetes, is 
occurring in both developing and developed 
countries which accounts for 5–10% of the total 
healthcare budget in many countries [4]. 
However, due to the prevalence of this disease in 
the world today and the serious threat posed to 
mankind’s health especially the aging, a lot of 
glucose-lowering drugs, insulin therapy, diet 
control and exercises have been used for the 
management of diabetes but total recovery           
have not been recorded [6]. Antidiabetic 
therapeutic drugs are directed towards 
increasing insulin secretion, decreasing insulin 
resistance and increasing insulin penetration into 
the cells [7]. The types of glucose-lowering 
drugs, includes insulin secretagogues 
(sulfonylureas, meglitinides), insulin sensitizers 
(biguanides, thiazolidinediones), the alpha-
glucosidase inhibitors (miglitol, acarbose) and 
the new peptide analogs being employed such 
as exenatide, liraglutide and dipeptidyl peptidase 
(DPP)-4 inhibitors [8]. 
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The liver which is the largest visceral organ of 
the body is often targeted for chemically induced 
organ toxicity, due to its strategic metabolic 
activity [9]. More than 900 drugs have been 
implicated in causing liver injury (drug induced 
hepatotoxicity) [10]. Diabetic patients who take 
oral hypoglycemics have a higher risk of 
developing drug-induced liver disease than those 
not taking these medications [11]. The first 
generation of these medications have been 
reported hepatotoxic which is one of the reason 
of withdrawal from the market [7]. Therefore 
proper monitoring of liver function is a necessity 
in treatment of diabetes to avoid idiosyncratic 
hepatotoxicity.  
 
The kidney is the major organ that carries out 
regulatory functions and excretion of toxic 
metabolites and drugs [12]. Nephrotoxic                
drugs exert toxic effects by altering 
intraglomerular hemodynamics, tubular cell 
toxicity, inflammation, crystal nephropathy, 
rhabdomyolysis, and thrombotic microangio-
pathy. Hypoglycaemia risk increases with 
increasing renal impairment (that is renal 
impairment is a major risk factor for 
hypoglycaemia), with hypoglycemia from 
antidiabetic drug therapy being among the four 
leading causes of hospitalisation for adverse 
drug reactions in the elderly [13]. 
 
The management of these complications can be 
a limiting factor to effective medication control 
due to possible drug-drug interactions and 
nonadherence to oral therapy by the diabetes 
patients [14]. Although previous researches have 
focused more on the oral treatment of diabetes, 
there is no well documented data on all these 
drugs with respect to their potential role in 
causing toxic effects. The management 
measures to achieve an effective blood glucose 
control or utilization, with a view to delaying or 
averting the onset of complications are however 
limited due to the associated toxic effects of 
antidiabetic medications. This work aims to 
assess the hepatotoxic and nephrotoxic effect of 
selected antidiabetic medications in type II 
diabetic patients within Ota, Nigeria. 
 
2. MATERIALS AND METHODS 
 
2.1 Participants 
 
The study population for this study included 225 
participants; 195 diabetic participants and 30 
healthy non-diabetic participants. This study was 
carried out in two facilities in Ota, Ogun State, 
they are: General Hospital, Ota, Ogun state, and 
ACE Medicare, Ota, Ogun State. The inclusion 
criteria included clinically diagnosed diabetic 
participants, currently on one or more oral 
antidiabetic drug(s), aged 18 years and above 
and healthy non-diabetic participants who are 
currently on no medication, as control. Healthy 
non-diabetic participants, currently on  
medication and unwilling diabetic subjects, not 
interested in being included in the research were 
excluded. 
 
2.2 Data Collection 
 
Questionnaire was used to collect all relevant 
information about the participants’ diabetes 
history, anthropometric and clinical data and life 
style habits. Intravenous blood sample (10 ml) 
was obtained from all participants by trained 
medical laboratory scientists for the assessment 
of the biochemical toxicological markers. 
Informed written consent was provided by all 
participants.  Ethical approval was obtained from 
Covenant University Ethics Committee, Ogun 
state and Nigeria Institute of Medical Research 
(NIMR) Ethics Committee, Lagos state with 
project approval number IRB/13/227. 
 
2.3 Sample Collection 
 
Intravenous blood sample (10 ml) was collected 
by trained medical laboratory scientists from 
Covenant University and Ado-Odo Ota Local 
Government Medical Laboratory, Ota, Ogun 
State. Collected blood samples were centrifuged 
at 3000 rpm for 10 minutes (min) using table top 
centrifuge (Model 0508-1) to obtain the serum.  
 
2.4 Biochemical Analysis 
 
The blood serum was analyzed for            
parameters such as: Urea, Creatinine, Alanine 
Aminotransferase (ALT), Albumin and Aspartate 
aminotransferase (AST) using Randox test kit 
(Randox Laboratories Limited, UK); Alkaline 
phosphatase (ALP) using ALP assay kit (TECO 
diagnostics). 
 
2.5 Determination of Protein Profile 
 
The Total protein in the blood serum was 
quantified using Biuret method according to the 
method described by Janairo et al. [15]. The 
protein profile in the blood serum was 
determined using Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
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according to standard experimental procedures 
of BIO- RAD laboratories, Inc. 
 
2.6 Clinical Limits for Blood Glucose 
Levels  
 
(American Diabetics Association (ADA), 2016) 
[1]. 
 
Normal fasting blood glucose - ≥ 90 ≤ 126 mg/dl, 
 
Normal random blood glucose - < 200 mg/dl 
 
2.7 Statistical Analysis  
 
The results obtained from this study was grouped 
and expressed as mean ± standard error of 
mean (SEM). Statistical analysis was carried out 
by one way analysis of variance with the 
Statistical Package for the Social Sciences 
(SPSS) version 15.0 (SPSS Inc., Chicago, IL, 
USA). The test for statistical significance was 
carried out at 95% confidence limit.  
 
3. RESULTS 
 
3.1 Effect of Antidiabetic Medications on 
Fasting and Random Blood Glucose 
Level of Diabetic Patients 
 
The effect of antidiabetic medications on fasting 
blood glucose and random blood glucose of 
diabetic patients was illustrated in Table 1. 
According to the criteria of (ADA, 2016), the 
mean range of controlled fasting blood glucose, 
random blood glucose are 90-126 mg/dl; <200 
mg/d respectively in diagnosed diabetic   
patients. 
 
Based on these criteria, in this study, diabetic 
groups on dietary control and metformin had their 
fasting and random blood glucose controlled, 
while diabetic groups on glimepiride; 
glibenclamide; metformin and glimepiride; 
metformin and glibenclamide and metformin, 
glibenclamide and glimepiride had uncontrolled 
fasting and random blood glucose (Table 1). 
 
3.2 Effect of Antidiabetic Medications on 
Kidney Function Markers in Blood 
Sample of Diabetic Patients 
 
The effect of antidiabetic medications on kidney 
function markers in diabetic patients was 
determined by assessment of the concentration 
of urea and creatinine (Table 2). There was no 
significant difference (p > 0.05) in the 
concentration of creatinine in all the diabetic 
medication groups when compared with diabetic 
dietary and non diabetic control groups, though 
there was insignificant increase (p > 0.05)  in the 
concentration of creatinine in all the groups 
except in the diabetic group using combination 
therapy of metformin, glimepiride and 
glibenclamide (Table 2). However, there was 
significant increase (p < 0.05) in the 
concentration of urea in diabetic group using 
meformin; metformin and glimepiride; metformin 
and glibenclamide when compared with diabetic 
dietary and non diabetic control groups (Table 2). 
 
3.3 Effect of Antidiabetic Medications on 
Liver Function Marker in Diabetic 
Patients 
 
The effect of antidiabetic medications on liver 
function markers in blood sample of diabetic 
patients was determined by evaluating the 
activity of alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, the 
concentration of albumin and total protein. There 
was significant increase (p < 0.05) in albumin 
concentration in diabetic groups using metformin; 
glimepiride; glibenclamide; metformin and 
glimepiride; metformin and glibenclamide, while 
there was no significant difference (p > 0.05) in 
the diabetic groups using combination therapy 
metformin, glimepiride and glibenclamide when 
compared to non-diabetic control group. Also, 
there was significant difference (p < 0.05) in the 
concentration of albumin in diabetic groups using 
glibenclamide and in the group using metfomin 
and glimepiride, while there was no significant 
difference (p > 0.05) in the diabetic groups using 
metformin; glimepiride; metformin and 
glibenclamide and in the group using metformin, 
glimepiride and glibenclamide when compared 
with diabetic dietary control group (Table 3).  
 
There was no significant difference (p > 0.05) in 
total protein in all the diabetic groups when 
compared with non-diabetic control group. 
However, there was significant increase (p < 
0.05) in total protein in diabetic groups using 
metformin; glibenclamide; metformin and 
glimepiride and the group using metformin and 
glibenclamide, while glimepiride; metformin, 
glimepiride and glibenclamide showed no 
significant difference (p > 0.05) when compared 
with diabetic dietary control (Table 3).  
 
 
 
 
 
Ogunlana et al.; JPRI, 30(1): 1-10, 2019; Article no.JPRI.51394 
 
 
 
5 
 
Table 1. Effects of antidiabetic medications on blood glucose of diabetic patients 
 
Markers/ Groups FBG (mg/dl) RBG (mg/dl) 
C 63.76±9.04N 50.9±9.10N   
DC 103.71±4.35C 120±5.00C 
MET   123.3±4.56
C
 189.18±13.11
C
 
GLIM   145.25±7.90
NC
 201.20±14.57
NC
    
GLIB    136.5±7.83
NC
 215.00±19.23
NC
 
MET&GLIM 162.57±13.48NC 274.17±33.78NC 
MET&GLIB 145.17±6.4NC 215.03±10.11NC 
MET, GLIM &GLIB 147.00± 17.76NC 225.00±7.16NC 
C = Control; DC = Dietary control; MET = Metformin; GLIM = Glimepiride; GLIB = Glibenclamide; FBG = Fasting 
blood glucose; RBG = Random blood glucose; BP = Blood pressure; 
N
, 
C
, and 
NC
 represents normal; controlled; 
and uncontrolled values respectively. Result expressed as mean ± SEM in 2 replicates 
 
Table 2. Effect of antidiabetic medications on kidney function markers in blood sample of 
diabetic patients 
 
Markers/ Groups Creatinine (Umol/L)     Urea (mmol/l) 
C 57.46 ± 7.28 1.76 ± 0.26 
DC 59.9 ± 14.03 1.95 ± 0.49 
MET 68.12 ± 6.60 3.00 ± 0.42*# 
GLIM 62.56 ± 8.08 2.42 ± 0.36 
GLIB 88.32 ± 6.58 3.24 ± 0.26 
MET & GLIM                                 68.16 ± 11.35    3.47 ± 0.59*# 
MET & GLIB           74.21 ± 4.81 3.13 ± 0.33*# 
MET, GLIM & GLIB   31.89 ± 15.95 0.95 ± 0.47 
C = Control; DC = Dietary control; MET = Metformin; GLIM = Glimepiride; GLIB = Glibenclamide. Values marked 
with * and # are significantly different at p < 0.05 when compared with healthy non diabetic control group and 
diabetic dietary control group respectively. Result expressed as mean ± SEM in 2 replicates 
 
Table 3. Effect of antidiabetic medication on liver function marker 
 
Markers/ Groups                       Albumin (g/l)                  T. Protein (mg/ml)    ALP (U/l) AST (U/l) ALT (U/l) 
C 22.01±3.21        0.45±0.031     14.60±1.72   6.39±0.25         4.11±0.31 
DC 23.22 ±5.93      0.36 ± 0.08     8.18 ± 3.07*      3.63 ± 1.20*     2.32 ±0.85* 
MET 33.36±2.89*      0.54±0.03#    17.18±1.54#      8.24±0.26#       2.92±0.32* 
GLIM 33.23±3.84*      0.44±0.04      17.10±2.12#      9.53±0.93#       3.07±0.41 
GLIB 50.40±1.37*# 0.55 ± 0.07    22.66 ± 0.12#    7.5 ± 0.22#       4.00 ± 0.10* 
MET & GLIM 35.08±4.15*#    0.50±0.05#    22.21±1.67*#    12.26±0.88*#   3.67±0.52 
MET & GLIB 35.11±1.99* 0.53±0.02#    18.28±1.19# 8.5±0.31#         2.71±0.21* 
MET,GLIM&GLIB 15.95±4.99       0.45±0.02      13.41±3.39        10±1.34#         0.50±0.25* 
C = Control; DC = Dietary control; MET = Metformin; GLIM = Glimepiride; GLIB = Glibenclamide; ALP = Alkaline 
Phosphatase; AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; T. PROT = Total Protein. 
Values marked with * and # are significantly different at p < 0.05 when compared with healthy non diabetic 
control group and diabetic dietary control group respectively. Result expressed as mean ± SEM in 5 replicates 
 
There was significant increase (p < 0.05) in the 
concentration of alkaline phosphatase (ALP) only 
in diabetic group using metformin and 
glimepiride, while the other diabetic groups using 
metformin; glimepiride; glibenclamide; metformin 
and glibenclamide and metformin, glibenclamide 
and glimepiride showed no significant difference 
(p > 0.05) when compared with non-diabetic 
control group. Furthermore, there was significant 
increase (p < 0.05) in the concentration of ALP in 
diabetic groups using metformin; glimepiride; 
glibenclamide; metformin and glimepiride; and 
metformin and glibenclamide, while there was no 
significant difference (p > 0.05) in the 
concentration of ALP only  in diabetic group 
using combination therapy metformin, glimepiride 
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and glibenclamide when compared with diabetic 
dietary control group (Table 3).  Also there was 
significant decrease (p < 0.05) in the 
concentration of ALP in the diabetic dietary 
control group compared with non-diabetic control 
group. 
 
However, there was significant increase (p < 
0.05) in concentration of aspartate amino-
transferase (AST) in diabetic group using 
combination therapy metformin and glimepiride 
and in the diabetic dietary control group, while 
there was no significant difference (p > 0.05) in 
the diabetic groups using metformin; glimepiride; 
glibenclamide; metformin and glibenclamide and 
metformin, glibenclamide and glimepiride, when 
compared with non-diabetic control group. Also, 
there was significant increase (p < 0.05) in the 
concentration of AST in all the diabetic 
medication groups when compared with diabetic 
dietary control group. 
 
There was no significant difference (p > 0.05) in 
concentration of alanine aminotransferase (ALT) 
in all the diabetic medication groups when 
compared with diabetic dietary control group 
(Table 3). However, there was significant 
decrease (p < 0.05) in the concentration of             
ALT in diabetic groups using metformin; 
glibenclamide; metformin and glibenclamide; 
metformin, glimepiride and glibenclamide and in 
the diabetic dietary control when compared with 
non-diabetic control group. While there was no 
significant difference (p > 0.05) in diabetic group 
using glimepiride and in the group using 
metformin and glimepiride (Table 3). 
 
3.4 Protein Profile Using Sodium Dodecyl 
Sulphate Polyacrylamide Gel 
Electrophoresis (Sds-Page) 
 
There was over-expression of a low molecular 
weight protein in the protein profile of diabetic 
participants using different medications in 
comparison with protein profile of non-diabetic 
participants. The molecular weight of the protein 
was determined in Plate 1. The molecular weight 
of the protein was determined to be 18 Kda. 
 
4. DISCUSSION 
 
Fasting blood glucose and random blood glucose 
(after meal) are part of the diagnosing criteria of 
diabetes and its control [1]. This study showed 
that diabetic groups using metformin and dietary 
control had well controlled blood glucose level 
this was reported in approximately 29.23% of the 
total diabetic participants in this study. Metformin 
and dietary control have been reported to be 
effective in reducing blood glucose level in 
diabetes patients mostly with newly diagnosed 
diabetes [16]. However, diabetic groups using 
glimepiride; glibenclamide; metformin and 
glimepiride; metformin and glibenclamide; 
metformin, glimepiride and glibenclamide had 
uncontrolled blood glucose level. The reasons for 
this are unknown but might be drug related which 
include drug-drug interactions, non-compliance 
by the patients, or other factors such as 
inappropriate dietary control where funds are 
limited, level of literacy, diabetic ketoacidosis or 
occult infections [17]. 
 
Diabetes is one of the leading causes of chronic 
renal disease and end stage renal disease. Drug-
induced nephrotoxicity may cause up to 20% of 
community and hospital acquired episodes of 
acute kidney injury (AKI) with incidence of 
approximately 30–40% among older adults. 
Kidney function was assessed in this study by 
measuring the concentration of urea, and 
creatinine in the serum of diabetic participants. 
The result of this study showed that there was no 
significant difference (p > 0.05) in the 
concentration of creatinine in the serum of 
diabetic groups compared to non-diabetic and 
dietary diabetic control groups (Table 2). This is 
in agreement with the findings of Stefan et al. 
(2004) and Thomsen et al. (2014), that creatinine 
is not a reliable biomarker in determining early 
damage to the kidney as it does not give an 
optimum expression of renal function [18,19]. 
However, the levels of urea increased 
significantly (p < 0.05) in the diabetic groups 
using metformin; metformin and glimepiride; 
metformin and glibenclamide. This can be as a 
result of associated lactic acidosis with metformin 
and prolonged hypoglycemia of the sulfonureas 
[20]. A report published by Strugaru et al. (2013) 
stated that the main situations that favor 
metformin-associated lactic acidosis are renal 
impairment and tissue hypoxia, which is 
dependent on associated pathologies and 
medication [21]. Therefore a baseline diagnosis 
and continuous renal diagnosis is required, when 
prescribing metformin. There was no significant 
increase (p > 0.05) in the concentration of 
creatinine and urea in diabetic patients using 
glibenclamide, when compared with non-diabetic 
and diabetic dietary control groups. This report is 
supported by the observation of Diwan et al. 
(2014) who stated that glibenclamide improves 
kidney and heart functions [22]. 
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Increased incidences of hepatotoxicity have been 
observed in patients with diabetes receiving drug 
therapies [23]. Hepatotoxicity in diabetic patients 
were assessed by evaluating the levels of 
albumin,  total protein, alkaline phosphatase 
(ALP), aspartate aminotransaminase (AST), 
alanine aminotransferase (ALT) in serum of 
diabetic patients. The result obtained showed 
that there was significant increase (p < 0.05) in 
the level of AST and ALP in the medication 
diabetic groups. This increase in ALP level might 
be due to possible billary dysfunction, while 
increase in AST might be due to pathological 
changes such as necrosis of hepatocytes, which 
causes increase in the level of amino-
transferases in the blood stream [24]. This result 
is consistent with the findings of Cone et al. 
(2010) who reported that metformin induce 
hepatic damage in type II diabetes mellitus with 
nonalcoholic fatty acid disease [25]. Also, 
combination of metformin with glimepiride has 
been reported to cause cholestatic hepatic injury 
associated with glimepiride [26]. There was 
significant decrease (p < 0.05) in the 
concentration of ALT in the diabetic groups using 
metformin; glibenclamide; metformin and 
glibenclamide; metformin, glimepiride and 
glibenclamide. This decrease signifies the 
hepatic protective property of these antidiabetic 
drugs.  
 
Increase in ALT has been reported to be specific 
for acute hepatocellular injury [27]. There was 
significant increase (p < 0.05) in the albumin 
concentration in diabetic groups using metformin; 
glimepiride; glibenclamide; metformin and 
glimepiride; metformin and glibenclamide; 
metformin, glimepiride and glibenclamide when 
compared with non-diabetic control group. This 
explains liver absence of hepatocellular 
dysfunction or damage to the liver [28]. Also, 
there was significant increase (p < 0.05) in serum 
total protein in diabetic groups using metformin; 
metformin and glimepiride; metformin and 
glibenclamide when compared with diabetic 
dietary control group. Total protein and albumin 
concentration has been reported to be 
qualitatively and quantitatively affected during 
liver damage [28]. 
 
 
                
Plate 1. Protein profiling of diabetic patients and non-diabetic patients’ using SDS PAGE 
electrophoresis 
MGG = Metformin, glimepiride, and glibenclamide; MGM = Metformin and glimepiride; 
MGB = Metformin and glibenclamide; M = Metformin; PL = Page Ruler Prestained Protein ladder (model 26616, 
Thermo Scientific, USA); C1, C2, C3, C4 = Control groups; Mwt (Kda) = Molecular weights of protein ladder 
expressed in kilo dalton 
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Result obtained from this study showed an over-
expression of a low molecular weight protein in 
the protein profile of diabetic groups using 
different medications, which was absent in the 
protein profile of the non-diabetic control groups. 
The molecular weight of the protein might be 
leptin. The significance of the over-expression of 
the proteins might be a signal for an increased 
risk in diabetes. 
 
Leptin has been reported as 18 kDa adipocytes 
secreted proteins, which not only affect the 
glucose homeostasis in the blood but also serve 
as important marker to study the progression of 
diabetes mellitus in obese individuals [29]. Leptin 
controls body weight by regulating metabolic 
behavior including; control of appetite and 
regulating energy expenditures [30]. It exerts 
pleiotropic effects by binding and activating 
specific leptin receptors (obR) in the 
hypothalamus and other organs [30].  However, 
in obese diabetic subjects, leptin binds with 
insulin receptors thereby causing insulin 
resistance. It also directly affects insulin 
sensitivity by regulating the efficiency of insulin-
mediated glucose metabolism by the skeletal 
muscle [31]. Also, leptin was reported as a 
marker of inflammation, which is closely 
associated with cardiovascular risk factors and 
cardiovascular and non-cardiovascular causes of 
death. This may explain the increased risk of 
diabetes, heart disease, increased blood 
pressure, insulin resistance and other chronic 
diseases in obese [31]. 
 
6. CONCLUSION 
 
In conclusion, increased organ toxicity and                
lack of proper glycemic control were reportedly 
associated with glimepiride and glibenclamide 
and their combination with metformin in                
diabetic groups in this study. Metformin was               
also reported in this study to induce renal and 
hepatic toxicity which might be due to the side 
effect of lactic acidosis, but the reported good 
glycemic control had made it effective. 
Emphatically, in this study, diabetic group using 
combination therapy of metformin and 
glimepiride had increased hepatotoxicity, 
increased nephrotoxicity and uncontrolled               
blood glucose level, indicating the damaging 
effect of this combination on this diabetic               
group in this study. Therefore it is suggested  
that control of diabetes is best carried out                  
with dietary control and lifestyle modification as 
well as good therapeutic drug monitoring for  
safe assessment of baseline organ function          
and avoidance of nephrotoxic drug combination. 
There was over-expression of a molecular  
weight protein which was suggested to be  
Leptin. This low molecular weight protein might 
serve as useful biomarkers in the monitoring of 
the progression of diabetes and its associated 
risk factors. Further studies with broader 
research are required as this may serve as 
useful tool in the assesssment of medication 
toxicity.  
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